← Back to Clinical Trials
Recruiting NCT04295148

NCT04295148 SEQUAR SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04295148
Status Recruiting
Phase
Sponsor Karolinska Institutet
Condition Anterior Cruciate Ligament Injuries
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2020-02-10
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
ACL Reconstruction with Semitendinosus graftACL Reconstruction with Quadriceps tendon-bone graft

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2020-02-10 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Randomized control trial comparing two different Anterior Cruciate Ligament (ACL) grafts in Anterior Cruciate Ligament Reconstruction: the semitendinosus hamstrings graft and the quadriceps graft. Capio Artro Clinic (Stockholm) has vast experience in ACL surgery using both semitendinosus and quadriceps grafts.

Eligibility Criteria

Inclusion Criteria: * Pre-injury Tegner Activity Scale≥7 * Intended return to sports to prior sport and Tegner Activity Scale Level * Time between injury and inclusion not more than 6 months * MR verified ACL rupture Exclusion Criteria: * Previous knee injury with symptoms before ACL injury * Neurological disease, inflammatory disease, connective tissue disease or balance disorder * Previous lower limb fracture or surgery * Laxity in the medial collateral ligament (MCL) and lateral collateral ligament (LCL) \> grade 1 * PCL rupture or Multiligament knee injury (MLKI) * Radiographic sign of osteoarthritis (OA) * Previous knee surgery or ligament injury in contralateral knee * Beighton score ≥ 5

Contact & Investigator

Central Contact

Anders Stålman, MD,Phd

✉ anders.stalman@ki.se

📞 0046736665957

Principal Investigator

Anders Stålman, MD,PhD

PRINCIPAL INVESTIGATOR

Karolinska Institutet

Frequently Asked Questions

Who can join the NCT04295148 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, up to 40 Years, studying Anterior Cruciate Ligament Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04295148 currently recruiting?

Yes, NCT04295148 is actively recruiting participants. Contact the research team at anders.stalman@ki.se for enrollment information.

Where is the NCT04295148 trial being conducted?

This trial is being conducted at Stockholm, Sweden.

Who is sponsoring the NCT04295148 clinical trial?

NCT04295148 is sponsored by Karolinska Institutet. The principal investigator is Anders Stålman, MD,PhD at Karolinska Institutet. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology